NCT06866236View on ClinicalTrials.gov

Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

July 31, 2027

Conditions
Chronic Kidney DiseasesAcute Kidney InjuryKidney Failure
Interventions
DRUG

QRX-3

capsule

Trial Locations (1)

77504

Neukidney Inc, Pasedena

All Listed Sponsors
lead

Ebima Clifford Okundaye

INDUSTRY

NCT06866236 - Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression | Biotech Hunter | Biotech Hunter